Pentoxifylline

Generic Name: Pentoxifylline

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₄O_₃

CAS Number: 6493-05-6

Unique Ingredient Identifier: SD6QCT3TSU

Background: Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication: Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions: Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease

Associated Therapies: -

Clinical Trials

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Conditions: Type 1 Diabetes Mellitus

First Posted Date: 2010-01-14

Last Posted Date: 2014-06-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01049633

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People

Phase 2

Completed

Conditions: HIV
Vascular Diseases
Cardiovascular Diseases
Atherosclerosis
HIV Infections

Interventions: Drug: Combination antiretroviral therapy (cART)
Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2009-03-19

Last Posted Date: 2014-05-12

Lead Sponsor: Indiana University

Target Recruit Count: 19

Registration Number: NCT00864916

Locations: 🇺🇸
Infectious Diseases Research Center, Indianapolis, Indiana, United States

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications

Phase 2

Completed

Conditions: Atherosclerosis
Cardiovascular Diseases
HIV

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2008-11-24

Last Posted Date: 2017-11-28

Lead Sponsor: Indiana University

Target Recruit Count: 26

Registration Number: NCT00796822

Locations: 🇺🇸
Indiana Clinical Research Center, Indianapolis, Indiana, United States

The Effects of Pentoxifylline on PAI-1 in an Obese Population

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: Pentoxifylline
Drug: Placebo

First Posted Date: 2008-10-10

Last Posted Date: 2017-11-30

Lead Sponsor: Vanderbilt University

Target Recruit Count: 37

Registration Number: NCT00770328

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)

Not Applicable

Conditions: Metabolic Parameters and Liver Histology

Interventions: Drug: Pentoxifylline
Drug: Pioglitazone

First Posted Date: 2008-05-21

Last Posted Date: 2008-05-21

Lead Sponsor: Govind Ballabh Pant Hospital

Target Recruit Count: 20

Registration Number: NCT00681733

Locations: 🇮🇳
Dr. Barjesh Chander Sharma, New Delhi, India

Pentoxifylline and Endometriosis

Phase 3

Completed

Conditions: Endometriosis-Associated Infertility

Interventions: Drug: placebo
Drug: pentoxifylline

First Posted Date: 2008-03-11

Last Posted Date: 2008-03-11

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 104

Registration Number: NCT00632697

Locations: 🇪🇸
Hospital Clinic, Barcelona, Spain

Treating the Resistant Patent Ductus Arteriosus (PDA)

Phase 2

Conditions: Patent Ductus Arteriosus

Interventions: Drug: Indomethacin
Drug: Pentoxifylline

First Posted Date: 2008-02-15

Last Posted Date: 2008-02-15

Lead Sponsor: Shaare Zedek Medical Center

Target Recruit Count: 68

Registration Number: NCT00616382

Locations: 🇮🇱
Neonatal Intensive Care Unit - Shaare Zedek Medical Center, Jerusalem, Israel

Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome

Phase 1

Terminated

Conditions: Hepatopulmonary Syndrome

Interventions: Drug: pentoxifylline

First Posted Date: 2008-01-15

Last Posted Date: 2015-03-09

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 9

Registration Number: NCT00593658

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Trental & Vitamin E for Radiation-Induced Fibrosis

Phase 2

Completed

Conditions: Fibrosis

Interventions: Drug: Pentoxifylline
Drug: Vitamin E

First Posted Date: 2007-12-31

Last Posted Date: 2013-01-29

Lead Sponsor: University of Iowa

Target Recruit Count: 54

Registration Number: NCT00583700

Locations: 🇺🇸
The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

Efficacy of Pentoxifylline on Primary Nephrotic Syndrome

Phase 3

Completed

Conditions: Nephrotic Syndrome

Interventions: Drug: Corticosteroid
Drug: pentoxifylline

First Posted Date: 2006-07-20

Last Posted Date: 2012-11-14

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 62

Registration Number: NCT00354731

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy